disease-modifying therapies

Overall Cost of DMTs Stable 2018ā€“2020, Study Finds

The overall cost of disease-modifying therapies for multiple sclerosis (MS) in the U.S. remained stable from 2018 to 2020, according to pharmacy and medical claims data from Prime Therapeuticsā€™ insured members. This stabilization derived from a balance between a reduction in Copaxone (glatiramer acetate injection) use due…

#ACTRIMS2021 ā€“ Taking Medication During Pregnancy Reduces Healthcare Costs

Editorā€™s note: TheĀ Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25ā€“27. GoĀ hereĀ to see the latest stories from the conference. Women with multiple sclerosis (MS) who continue taking disease-modifying therapies (DMTs) throughout pregnancy accrue lower non-maternity healthcare…

National MS Society Urges DMT Dosing Changes for COVID-19 Vaccinations

To potentially increase the effectiveness of COVID-19 vaccines in people with multiple sclerosis (MS), the National Multiple Sclerosis Society is recommending dosing adaptations for some disease-modifying therapies (DMTs). Based on expert consensus and available data, the guidance is particularly relevant for MS patients considering initiating or already being…

#MSVirtual2020 – Pediatric MS Patients May Do Best on Intravenous DMTs, Study Finds

Most children and adolescents with pediatric-onset multiple sclerosis (POMS), especially those treated intravenously with a disease-modifying therapyĀ (DMT), achieve no evidence of disease activity within two years of diagnosis, according to a real-life study from the U.S. Patients whose DMTs are infused into a vein (intravenous treatment) areĀ more likely…

More Research Needed Into How Exercise, Rehab Aid Cognition in MS

Cognitive problems are common in people with multiple sclerosis (MS) but inadequately addressed by disease-modifying therapies, whileĀ cognitive rehabilitation and exercise training programs can be effective, a review study reported.Ā  Research studies of exercise programs need to include larger groups of patients with demonstrated cognitive difficulties, however, and more pharmacological…

Ocrevus Use Still Growing in Europe But Challenges on Horizon, Spherix Reports

Prescriptions ofĀ Rocheā€™sĀ OcrevusĀ (ocrelizumab) among multiple sclerosis (MS) patients initiating or switching aĀ disease-modifying therapy (DMT) continue to rise in Europe, according toĀ a surveyĀ conducted byĀ Spherix Global Insights. Ocrevus, an anti-CD20 monoclonal antibody administered directly into a vein,Ā was approved in the European UnionĀ to treat active forms…

Tysabri May Promote Inflammatory B-Cell Activation in MS Patients, Study Says

Tysabri (natalizumab), an effective T-cell targeting treatment for multiple sclerosisĀ (MS),Ā seems to also promote the activation of pro-inflammatory immune B-cells in people with this disease, a studyĀ found. The study, “Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients,” was published in the…

RRMS Patients Not Using DMTs More Likely to Have Been Misdiagnosed, Cite Poorer Relationships with Doctors, Survey Says

People with relapsing-remitting multiple sclerosis (RRMS) who don’t use disease-modifying therapies (DMTs) are more likely to have been misdiagnosed previously, and to have poorer relationships with their healthcare providers, the results of a new survey suggest. The survey, titled “Multiple Sclerosis In America 2019,” was conducted byĀ …